Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura.
about
Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical useA randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.Treatment of thrombotic thrombocytopenic purpura.Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura.Investigational drugs in thrombotic thrombocytopenic purpura.Main Properties of the THERAFLEX MB-Plasma System for Pathogen ReductionPlasma components: properties, differences, and uses.Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study.A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy.Role of Riboflavin- and UV Light-Treated Plasma in Prevention of Transfusion-Related Acute Lung Injury.Component pathogen inactivation: a critical review.Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasmaRecommendations for the transfusion of plasma and platelets.A comparison of methods of pathogen inactivation of FFP.Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period.Update on the use of pathogen-reduced human plasma and platelet concentrates.Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen.
P2860
Q26741073-ADEC7BE6-9600-410B-B474-D12376E04CABQ30441694-ABF00F2C-900E-4FE3-A852-66E6DD839A35Q33370956-2F01EE84-71DE-4EAD-BE86-93E99D2C2948Q33376161-A5A8EE36-BD92-405E-BCCA-91C08404F6C6Q33395696-DE99A772-74A4-4800-A087-4B30DBE16140Q33396311-3D95A6DD-A2F9-4325-8610-8275C520D1C6Q33401173-38A99A97-2BAB-4F6F-8CA2-A04E8ED9EBE5Q33424405-6C5EC6DC-DB4E-4BAD-8662-E2D1AA097759Q33436241-1B91F1EA-250A-4D7B-A4DC-3C4C356292CFQ33863382-F249322E-BF4C-4A8C-9BE1-4CE518D471A3Q34310415-9C011F99-7CA7-4481-9E88-D4FB14C9DCCAQ37062415-0C04A02E-F083-46CF-8C93-21F39A87E43CQ37209117-8289F265-A096-4B49-AC49-05D05C99C864Q37776318-6348FD7C-DF7D-4A56-BFCD-9FE213998EA0Q37789774-1F68FE80-4FDB-4CE2-AD36-40E13B0D2F74Q38109665-37D649D6-E73F-4885-92CC-FBA2B5AF66FFQ46978173-5E657C92-C870-4D44-965D-CB07E191D35A
P2860
Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Methylene blue-photoinactivate ...... otic thrombocytopenic purpura.
@ast
Methylene blue-photoinactivate ...... otic thrombocytopenic purpura.
@en
type
label
Methylene blue-photoinactivate ...... otic thrombocytopenic purpura.
@ast
Methylene blue-photoinactivate ...... otic thrombocytopenic purpura.
@en
prefLabel
Methylene blue-photoinactivate ...... otic thrombocytopenic purpura.
@ast
Methylene blue-photoinactivate ...... otic thrombocytopenic purpura.
@en
P2093
P2860
P1433
P1476
Methylene blue-photoinactivate ...... botic thrombocytopenic purpura
@en
P2093
Alvarez-Larrán A
Muncunill J
P2860
P304
P356
10.1111/J.0042-9007.2004.00506.X
P50
P577
2004-05-01T00:00:00Z